• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

DNA-based vaccine, ZyCoV-D, is safe and efficacious against COVID-19 infection for patients aged 12 years and older

byNeel MistryandTeddy Guo
April 12, 2022
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Seroconversion at 84 days was greater in the ZyCoV-D group compared to placebo.

2. The occurrence of adverse events was comparable with one (not treatment-related) death occurring in each group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Vaccines are crucial in the fight against COVID-19. Until now, vaccines have been manufactured by various healthcare agencies around the world. Many of these are RNA-based vaccines which must be stored at specific temperatures for viability. ZyCoV-D is a DNA-based vaccine produced by Cadila Healthcare that has been shown to be stable at storage temperatures of 2-8oC. However, little is known about its clinical effectiveness at the population level. This double-blind randomized trial aimed to evaluate the safety and efficacy of ZyCoV-D in patients with no SARS-CoV-2 infection at baseline. The primary outcome was prevalence of symptomatic RT-PCR-confirmed COVID-19 at day 84 (28 days after the third dose), while key secondary outcomes were frequency of severe COVID-19 cases and confirmed COVID-19 deaths. According to study results, patients assigned to the ZyCOV-D (vaccine) group developed a greater immunity response to SARS-CoV-2 compared to those in the placebo group. There were no reported cases of moderate or severe COVID-19 infection in the vaccine group. Conversely, the placebo group reported one severe and three moderate COVID-19 cases during the study period. A major limitation of this study may be the low number of total COVID-19 cases, with only 81 cases included in the efficacy analysis between both groups.

Click to read the study in The Lancet

Relevant Reading: Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection

RELATED REPORTS

Worsening kidney function observed following SARS-CoV-2 infection in children

Hospital-onset antimicrobial resistance increased during COVID-19 pandemic

The 2 Minute Medicine Podcast Episode 55

In-depth [randomized-controlled trial]: Between Jan 16 and June 23, 2021, 33 194 patients were screened for eligibility across 49 centers in India. Included were those aged ≥ 12 years with no known SARS-CoV-2 at baseline. Altogether, 27 701 patients (13 849 to ZyCoV-D and 13 852 to placebo) were included in the safety analysis. In the efficacy analysis, only 81 patients were eligible (20 to ZyCoV-D and 61 to placebo). The majority (67.1%) were male with a mean age of 36.5 years (standard deviation [SD] 13.8). Seroconversion at 84 days (i.e., 28 days after the third vaccine dose) was significantly greater in the ZyCoV-D group (n=44, 88.0%) compared to the placebo group (n=20, 42.6%; p<0.0001). The intervention group also reported greater antibody titres (26.7, 95% CI 17.4-41.0) compared to placebo (5.7, 95% CI 3.1-10.5). Moreover, the incidence of adverse events was comparable between both groups (n=623, 4.5% in the ZyCoV-D group vs. n=620, 4.5% in the placebo group), while overall vaccine efficacy was estimated to be 66.7%. Overall, findings from this study suggest that ZyCoV-D was both safe and effective in asymptomatic patients with no SARS-CoV-2 infection at baseline.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: CoronavirusCOVID-19DNA vaccineSARS-CoV-2vaccineZyCoV-DZyCoV-D vaccine
Previous Post

#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers

Next Post

#VisualAbstract: Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer

RelatedReports

Being overweight and obese associated with increased incidence of chronic kidney disease
Chronic Disease

Worsening kidney function observed following SARS-CoV-2 infection in children

May 23, 2025
High risk of complications, but low mortality among children with MRSA bacteremia
Infectious Disease

Hospital-onset antimicrobial resistance increased during COVID-19 pandemic

April 28, 2025
The 2 Minute Medicine Podcast Episode 15
2MM Podcast

The 2 Minute Medicine Podcast Episode 55

April 5, 2025
The Scan by 2 Minute Medicine: The Role of Virtual Reality in Pain Management, WHO’S controversial diagnosis on gaming addictions, the TikTok ban and psychology of doom scrolling, and the risk of smart devices replacing annual checkups
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Triple Attack Against Endometriosis, Vaccines and Autism, Revisited, The Final Frontier of Human Health, and Eating Well to Live Better:

April 1, 2025
Next Post
#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis

#VisualAbstract: Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer

#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers

#VisualAbstract: Nivolumab plus chemotherapy improves progression-free survival in gastric or gastroesophageal junction cancer

Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial

Initiation of targeted disease-modifying antirheumatic drugs in patients with rheumatoid arthritis not associated with reduced risk of Alzheimer disease and related dementia

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravaginal conjugated oestrogen does not improve continuation rate of ring pessary use
  • Artificial intelligence based clinical decision systems are safe and effective for diabetes management
  • Epic Launchpad propels generative-AI into everyday hospital routines
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.